FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPRO | VAL |
|------------------------|-----------|
| OMB Number: | 3235-0287 |
| Estimated average burd | en |
| hours per response: | 0.5 |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | d Address of | <u>V</u> | 2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX] | | | | | | | | | applio irecto | , | 1 | , 0% Ov | vner | | | | | |
|------------------------------------------------------------------------------------|-----------------------------------------------------------------------|--------------------------------------------|--------------------------------------------------------------------------------------|---------------------------------|------------------------------|------------------------------------------------------------------------------------------------------------------------|-------|-----------------------------------------|------------------------------------------------|------------------------------|-----------------------|------------------------------------------------------------------------------------------------|----------------------------------------|-----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|-----------------------------------------------------|--------------------------------------------------------------------|--|--|
| (Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 10/12/2016 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | elow) | | t | Other (selow) | | | |
| (Street) BOSTON MA 02210 | | | | - · · · - | | | | | | | | | | | Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | |
| (City) | (3) | | (Zip) le I - N | lon-Deriv | vative | Sec | uriti | ies Ac | auire | d. D | isposed c | of. or Be | eneficia | llv Ov | vned | l | | | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date | | | | 2. Transac | tion | 2A. Deemed Execution Date, | | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) o | | (A) or | 5. Amount of | | int of es ally | 6. Owners Form: Dir (D) or Indi (I) (Instr. 4 | ect rect | 7. Nature of Indirect Beneficial Ownership | | | |
| | | | | | | | | | Code | v | Amount | (A) or (D) | Price | Tr | | d tion(s) and 4) | | | (Instr. 4) | | |
| Common Stock 10/12/2 | | | | | 2016 | | | | M | | 6,500 | Α | \$36.3 | | 274 | 1,725 | D | | | | |
| Common Stock 10/12/20 | | | | | 2016 | | | | S ⁽¹⁾ | | 4,100 | D | \$80.79 | ⁹⁽²⁾⁽³⁾ 270 | |),625 | D | | | | |
| Common Stock 10/12/20 | | | | | 2016 | | | | S ⁽¹⁾ | | 1,400 | D | \$81.28 | (2)(4) 269 | |),225 | D | | | | |
| Common Stock 10/12/20 | | | | | 2016 | | | | S ⁽¹⁾ | | 1,000 | D | \$82.35 | (2)(5) 268 | | 3,225 | D | | | | |
| Common Stock | | | | | | | | | | | | | | | 13 | ,286 | I | | 401k | | |
| Common Stock | | | | | | | | | | | | | | | 78,200 | | I | | Common Stock Held In Trust | | |
| | | ī | able I | | | | | | | | posed of, converti | | | y Owr | ned | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | if any | emed ion Date, /Day/Year) | 4. Transa Code (8) | | | | 6. Date Exerc Expiration Da (Month/Day/N | | ate | 7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | | 9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4) | Owner Form: Direct or Indi (I) (Ins | n: ct (D) direct | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | Code | v | (A) | (D) | Date Exercis | sable | Expiration Date | Title | Amount or Number of Shares | | | | | | | | |
| Stock Option (Right to Buy) | \$36.3 | 10/12/2016 | | | M | | | 6,500 | (6) | | 01/23/2017 | Common Stock | 6,500 | \$0. | 00 | 86,000 | | D | | | |

Explanation of Responses:

- $1.\ Transaction\ made\ pursuant\ to\ Dr.\ Boger's\ company\ approved\ trading\ plan\ under\ Rule\ 10b5-1.$
- 2. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 3. Open market sales reported on this line occurred at a weighted average price of \$80.79 (range \$80.13 to \$81.12).
- $4. Open \ market \ sales \ reported \ on \ this \ line \ occurred \ at \ a \ weighted \ average \ price \ of \$81.28 \ (range \$81.16 \ to \$81.94).$
- 5. Open market sales reported on this line occurred at a weighted average price of \$82.35 (range \$82.20 to \$82.57).
- 6. Fully vested.

Remarks:

Omar White, Attorney-In-Fact 10/14/2016

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.